Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Rovi Pharmaceuticals Laboratories
- Target Recruit Count
- 46
- Registration Number
- NCT03363477
Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2022-02-22
- Target Recruit Count
- 2055
- Registration Number
- NCT03363035
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳The First Hospital of Changsha, Changsha, Hunan, China
🇨🇳The Second People's Hospital of Hunan Province, Changsha, Hunan, China
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 80
- Registration Number
- NCT03339349
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2020-05-20
- Target Recruit Count
- 12
- Registration Number
- NCT03296982
Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 122
- Registration Number
- NCT03296033
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 438
- Registration Number
- NCT03277001
- Locations
- 🇨🇳
Huashan hospital,Fudan university, Shanghai, Shanghai, China
FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 813
- Registration Number
- NCT03276143
- Locations
- 🇱🇹
Republican Vilnius University Hospital, Vilnius, Lithuania
🇵🇱Wojewódzki Szpital Zespolony, Kielce, Poland
🇵🇱Szpital Specjalistyczny im. Rydygiera, Krakow, Poland
Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2018-04-19
- Target Recruit Count
- 22
- Registration Number
- NCT03146858
- Locations
- 🇬🇧
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom
Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- TeaRx LLC
- Target Recruit Count
- 200
- Registration Number
- NCT03088358
- Locations
- 🇷🇺
St. Petersburg State Institution of Health "City Hospital № 2", Saint Petersburg, Russian Federation
🇷🇺SHI of the city of Moscow City Clinical Hospital n.a. S.P. Botkin, Moscow, Russian Federation
🇷🇺SHAI "Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan", Kazan, Russian Federation
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Portola Pharmaceuticals
- Target Recruit Count
- 153
- Registration Number
- NCT03083704
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.